<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502915</url>
  </required_header>
  <id_info>
    <org_study_id>16-1569</org_study_id>
    <nct_id>NCT03502915</nct_id>
  </id_info>
  <brief_title>Nitrous Oxide for External Cephalic Version</brief_title>
  <official_title>Randomized Controlled Trial of Nitrous Oxide Analgesia in External Cephalic Version (ECV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine the effectiveness of nitrous oxide in reducing the anxiety and
      pain associated with external cephalic version (ECV); a maneuver to turn the fetus from
      breech to cephalic position.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:

      Potential subjects will be identified as they are scheduled to undergo ECV at the UNC
      Department of Obstetrics and Gynecology. Subjects will be enrolled in the study by one of the
      study investigators. Details of the study will be reviewed with potential subjects and those
      wishing to enroll in the study will be consented for the study by one of the study
      investigators. Once enrolled participants will be randomized to receive either a mixture of
      50% nitrous oxide in 50% oxygen or 100% oxygen, both of which will be delivered via the
      Nitronox apparatus. Demographic variables will be recorded for each participant at the time
      they are enrolled in the study

      The Nitronox apparatus will be set up to deliver either 50% nitrous oxide in 50% oxygen or
      100% oxygen by an anesthesia provider covering labor and delivery who is not involved in the
      study. The Nitronox device will be covered to prevent participants, study investigators and
      obstetricians performing the procedure from knowing whether nitrous oxide is being delivered.
      Nitrous oxide is odorless and colorless, so in that way is indistinguishable from oxygen.

      Participants will be prepared for ECV according to current protocols for ECV at UNC. IV
      access will be obtained and tocolytic agents will be given according to current practice and
      protocols. Monitoring of maternal and fetal vital signs will be done according to current
      protocols.

      Immediately before an ECV attempt participants will breathe through the facemask of the
      Nitronox device for 30 seconds and will then be free to use the device ad lib during the ECV
      attempt. Immediately following each attempt, while fetal monitoring is occurring, the
      participants will be asked to rate their maximum pain score during the previous attempt. They
      will also be asked to rate their current level of anxiety. This process will be repeated for
      any further ECV attempts.

      At conclusion of all ECV attempts, while fetal monitoring is occurring, the participants will
      be asked to rate their current level of pain, their satisfaction with the procedure and about
      any side effects they experienced (nausea, vomiting, dizziness, headache, other).
      Participants will continue to be monitored on labor and delivery as current protocol
      dictates, typically 30 minutes of maternal and fetal monitoring if there are no complications
      and fetal status is reassuring.

      Following the procedure, the obstetrician who performed the procedure will be asked to rate
      how difficult they felt it was to perform the procedure and to rate how much they felt the
      analgesic provided assisted in performing the procedure. They will also be asked to indicate
      whether they thought the patient was in the treatment or placebo arm of the study. This will
      be recorded to address the adequacy of blinding.

      All study variables will be assessed and recorded by one of the study investigators to ensure
      consistency in data collection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2017</start_date>
  <completion_date type="Actual">February 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Nitronox device will be covered. The person setting up the device with either 100% oxygen or 50% nitrous/50% oxygen, will not be participating in the study. The patient, investigator and labor and delivery personnel (obstetrician and nursing staff) will be blinded as to the medication being administered during the procedure.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Score Experienced During Version</measure>
    <time_frame>During each version procedure, a total average of up to approximately 30 minutes</time_frame>
    <description>Pain scores will be collected following each version attempt using an 11 point scale (with 0 being no pain at all; 10 being worst pain imaginable), ranging from 0 to 10. Higher scores indicate more pain, lower scores indicate less pain. If more than one attempt, pain scores will be averaged to obtain a single score for the entire procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Anxiety Score Experienced During Version</measure>
    <time_frame>During each version procedure, a total average of up to approximately 30 minutes</time_frame>
    <description>Anxiety scores will be collected following each version attempt using an 11 point scale (0 being not at all anxious; 10 being extremely anxious), ranging from 0 to 10. Higher scores indicate more anxiety, lower scores indicate less anxiety. If more than one attempt, anxiety scores will be averaged to obtain a single score for the entire procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Post-procedure Pain Score</measure>
    <time_frame>Immediately Post-procedure, within approximately 15 minutes of final version attempt</time_frame>
    <description>Pain scores will be collected following completion of the version using an 11 point scale (0 being no pain at all; 10 being worst pain imaginable), ranging from 0 to 10. Higher scores indicate more pain, lower scores indicate less pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Post-procedure Patient Satisfaction Score</measure>
    <time_frame>Immediately Post-procedure, within approximately 15 minutes of final version attempt</time_frame>
    <description>Satisfaction will be assessed following the procedure using an 11 point scale (0 being not at all satisfied; 10 being extremely satisfied), ranging from 0 to 10. Higher scores indicate more satisfaction, lower scores indicate less satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Post-procedure Provider Assessed Level of Difficulty Score</measure>
    <time_frame>Immediately Post-procedure, within approximately 15 minutes of final version attempt</time_frame>
    <description>Following the procedure, the obstetric provider performing the procedure will rate the ease of procedure on a 1-10 scale (1 being very easy and 10 being extremely difficult), ranging from 1 to 10. Higher scores indicate more difficulty, lower scores indicate less difficulty. A 10 point scale was used for this outcome, while an 11 point scale was used for the other 4 outcome measures (pain, anxiety, post-procedure pain and satisfaction).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>External Cephalic Version</condition>
  <arm_group>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive nitrous oxide during the version procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo (100% oxygen) during the version procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide</intervention_name>
    <description>50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <other_name>Laughing gas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100% oxygen via Nitronox delivery device</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female 18 years or greater

          -  Scheduled to undergo external cephalic version due to singleton breech presentation

          -  Not scheduled to have spinal or epidural anesthesia during the version procedure

          -  American Society of Anesthesiology (ASA) Physical Status 1, 2 or 3.

          -  Able to provide informed consent and adhere to study protocol

        Exclusion Criteria:

          -  Current or historical evidence of any clinically significant disease or condition,
             especially cardiovascular or neurological conditions that, in the opinion of the
             Investigator, may increase the risk of exposure to nitrous oxide or complicate the
             subject's post-procedural course.

          -  Significant medical conditions or laboratory results that, in the opinion of the
             Investigator, indicate an increased vulnerability to study drugs and procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only females will participate because only females can be pregnant.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen A. Smith, MD, FASA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)02840-3/fulltext</url>
    <description>Lancet 2000 CD versus breech VD</description>
  </link>
  <link>
    <url>http://vb3lk7eb4t.search.serialssolutions.com.libproxy.lib.unc.edu/?sid=Entrez:PubMed&amp;id=pmid:16816088</url>
    <description>ACOG committee opinion 340</description>
  </link>
  <link>
    <url>https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1111/j.0001-6349.2005.00505.x</url>
    <description>Pain During Version</description>
  </link>
  <link>
    <url>https://link.springer.com/content/pdf/10.1007%2Fs12630-010-9278-4.pdf</url>
    <description>Neuraxial for version</description>
  </link>
  <link>
    <url>http://vb3lk7eb4t.search.serialssolutions.com.libproxy.lib.unc.edu/?sid=Entrez:PubMed&amp;id=pmid:18055730</url>
    <description>Neuraxial for version</description>
  </link>
  <link>
    <url>http://vb3lk7eb4t.search.serialssolutions.com.libproxy.lib.unc.edu/?sid=Entrez:PubMed&amp;id=pmid:24356165</url>
    <description>Nitrous for labor pain</description>
  </link>
  <link>
    <url>http://vb3lk7eb4t.search.serialssolutions.com.libproxy.lib.unc.edu/?sid=Entrez:PubMed&amp;id=pmid:19955510</url>
    <description>Neuroapoptosis</description>
  </link>
  <link>
    <url>http://www.jneurosci.org/content/jneuro/23/3/876.full.pdf</url>
    <description>anesthetic gases and apoptosis</description>
  </link>
  <link>
    <url>http://vb3lk7eb4t.search.serialssolutions.com.libproxy.lib.unc.edu/?sid=Entrez:PubMed&amp;id=pmid:22273829</url>
    <description>remi for labor analgesia</description>
  </link>
  <reference>
    <citation>Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR. Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial. Term Breech Trial Collaborative Group. Lancet. 2000 Oct 21;356(9239):1375-83.</citation>
    <PMID>11052579</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 340. Mode of term singleton breech delivery. Obstet Gynecol. 2006 Jul;108(1):235-7.</citation>
    <PMID>16816088</PMID>
  </reference>
  <reference>
    <citation>Fok WY, Chan LW, Leung TY, Lau TK. Maternal experience of pain during external cephalic version at term. Acta Obstet Gynecol Scand. 2005 Aug;84(8):748-51.</citation>
    <PMID>16026399</PMID>
  </reference>
  <reference>
    <citation>Lavoie A, Guay J. Anesthetic dose neuraxial blockade increases the success rate of external fetal version: a meta-analysis. Can J Anaesth. 2010 May;57(5):408-14. doi: 10.1007/s12630-010-9278-4. Epub 2010 Feb 3.</citation>
    <PMID>20127530</PMID>
  </reference>
  <reference>
    <citation>Weiniger CF, Ginosar Y, Elchalal U, Sharon E, Nokrian M, Ezra Y. External cephalic version for breech presentation with or without spinal analgesia in nulliparous women at term: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1343-50.</citation>
    <PMID>18055730</PMID>
  </reference>
  <reference>
    <citation>Likis FE, Andrews JC, Collins MR, Lewis RM, Seroogy JJ, Starr SA, Walden RR, McPheeters ML. Nitrous oxide for the management of labor pain: a systematic review. Anesth Analg. 2014 Jan;118(1):153-67. doi: 10.1213/ANE.0b013e3182a7f73c. Review. Erratum in: Anesth Analg. 2014 Apr;118(4):885.</citation>
    <PMID>24356165</PMID>
  </reference>
  <reference>
    <citation>Rosen MA. Nitrous oxide for relief of labor pain: a systematic review. Am J Obstet Gynecol. 2002 May;186(5 Suppl Nature):S110-26. Review.</citation>
    <PMID>12011877</PMID>
  </reference>
  <reference>
    <citation>Creeley CE, Olney JW. The young: neuroapoptosis induced by anesthetics and what to do about it. Anesth Analg. 2010 Feb 1;110(2):442-8. doi: 10.1213/ANE.0b013e3181c6b9ca. Epub 2009 Dec 2.</citation>
    <PMID>19955510</PMID>
  </reference>
  <reference>
    <citation>Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003 Feb 1;23(3):876-82.</citation>
    <PMID>12574416</PMID>
  </reference>
  <reference>
    <citation>Schnabel A, Hahn N, Broscheit J, Muellenbach RM, Rieger L, Roewer N, Kranke P. Remifentanil for labour analgesia: a meta-analysis of randomised controlled trials. Eur J Anaesthesiol. 2012 Apr;29(4):177-85. doi: 10.1097/EJA.0b013e32834fc260.</citation>
    <PMID>22273829</PMID>
  </reference>
  <reference>
    <citation>Mu√±oz H, Guerra S, Perez-Vaquero P, Valero Martinez C, Aizpuru F, Lopez-Picado A. Remifentanil versus placebo for analgesia during external cephalic version: a randomised clinical trial. Int J Obstet Anesth. 2014 Feb;23(1):52-7. doi: 10.1016/j.ijoa.2013.07.006. Epub 2014 Jan 3.</citation>
    <PMID>24388737</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <results_first_submitted>October 7, 2019</results_first_submitted>
  <results_first_submitted_qc>October 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breech presentation</keyword>
  <keyword>nitrous oxide</keyword>
  <keyword>analgesia</keyword>
  <keyword>pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>9-36 months after publication</ipd_time_frame>
    <ipd_access_criteria>Approval from an IRB, IEC, or REB and an executed data use/sharing agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03502915/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nitrous Oxide</title>
          <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
        </group>
        <group group_id="P2">
          <title>Oxygen</title>
          <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nitrous Oxide</title>
          <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
        </group>
        <group group_id="B2">
          <title>Oxygen</title>
          <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="4.7"/>
                    <measurement group_id="B2" value="31.8" spread="4.3"/>
                    <measurement group_id="B3" value="32.1" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baby Weight</title>
          <description>Newborn weight at time of delivery</description>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3631.8" spread="491.2"/>
                    <measurement group_id="B2" value="3242.4" spread="416.6"/>
                    <measurement group_id="B3" value="3433.1" spread="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Amniotic Fluid Index (AFI)</title>
          <description>AFI is determined using ultrasound to measure the deepest vertical pocket of fluid in each quadrant. The four measurements are then added to calculate the AFI in cm. AFI between 8-18cm is considered normal. AFI &lt; 5-6cm is considered low. AFI &gt; 24-25cm is considered excessive. AFI &gt; 10cm has been shown to be associated with successful ECV.</description>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="4.5"/>
                    <measurement group_id="B2" value="11.1" spread="4.2"/>
                    <measurement group_id="B3" value="11.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <description>Gestational age of the patient at the time of version procedure.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="0.4"/>
                    <measurement group_id="B2" value="37.2" spread="0.4"/>
                    <measurement group_id="B3" value="37.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Basal Metabolic Rate</description>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="5.1"/>
                    <measurement group_id="B2" value="31" spread="6.3"/>
                    <measurement group_id="B3" value="30.2" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Score Experienced During Version</title>
        <description>Pain scores will be collected following each version attempt using an 11 point scale (with 0 being no pain at all; 10 being worst pain imaginable), ranging from 0 to 10. Higher scores indicate more pain, lower scores indicate less pain. If more than one attempt, pain scores will be averaged to obtain a single score for the entire procedure.</description>
        <time_frame>During each version procedure, a total average of up to approximately 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
            <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Score Experienced During Version</title>
          <description>Pain scores will be collected following each version attempt using an 11 point scale (with 0 being no pain at all; 10 being worst pain imaginable), ranging from 0 to 10. Higher scores indicate more pain, lower scores indicate less pain. If more than one attempt, pain scores will be averaged to obtain a single score for the entire procedure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.486" spread="2.307"/>
                    <measurement group_id="O2" value="5.433" spread="2.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margin is the standard error of the estimated difference.</non_inferiority_desc>
            <p_value>0.943</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.508</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.402</ci_lower_limit>
            <ci_upper_limit>1.507</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Anxiety Score Experienced During Version</title>
        <description>Anxiety scores will be collected following each version attempt using an 11 point scale (0 being not at all anxious; 10 being extremely anxious), ranging from 0 to 10. Higher scores indicate more anxiety, lower scores indicate less anxiety. If more than one attempt, anxiety scores will be averaged to obtain a single score for the entire procedure.</description>
        <time_frame>During each version procedure, a total average of up to approximately 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
            <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Anxiety Score Experienced During Version</title>
          <description>Anxiety scores will be collected following each version attempt using an 11 point scale (0 being not at all anxious; 10 being extremely anxious), ranging from 0 to 10. Higher scores indicate more anxiety, lower scores indicate less anxiety. If more than one attempt, anxiety scores will be averaged to obtain a single score for the entire procedure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.696" spread="2.969"/>
                    <measurement group_id="O2" value="4.253" spread="2.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margin is the standard error of the estimated difference.</non_inferiority_desc>
            <p_value>0.597</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.443</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.867</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.229</ci_lower_limit>
            <ci_upper_limit>2.114</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Post-procedure Pain Score</title>
        <description>Pain scores will be collected following completion of the version using an 11 point scale (0 being no pain at all; 10 being worst pain imaginable), ranging from 0 to 10. Higher scores indicate more pain, lower scores indicate less pain.</description>
        <time_frame>Immediately Post-procedure, within approximately 15 minutes of final version attempt</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
            <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Post-procedure Pain Score</title>
          <description>Pain scores will be collected following completion of the version using an 11 point scale (0 being no pain at all; 10 being worst pain imaginable), ranging from 0 to 10. Higher scores indicate more pain, lower scores indicate less pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.155"/>
                    <measurement group_id="O2" value="0.88" spread="1.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margin is the standard error of the estimated difference.</non_inferiority_desc>
            <p_value>0.748</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.280</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.629</ci_lower_limit>
            <ci_upper_limit>0.869</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Post-procedure Patient Satisfaction Score</title>
        <description>Satisfaction will be assessed following the procedure using an 11 point scale (0 being not at all satisfied; 10 being extremely satisfied), ranging from 0 to 10. Higher scores indicate more satisfaction, lower scores indicate less satisfaction.</description>
        <time_frame>Immediately Post-procedure, within approximately 15 minutes of final version attempt</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
            <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Post-procedure Patient Satisfaction Score</title>
          <description>Satisfaction will be assessed following the procedure using an 11 point scale (0 being not at all satisfied; 10 being extremely satisfied), ranging from 0 to 10. Higher scores indicate more satisfaction, lower scores indicate less satisfaction.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.286" spread="4.027"/>
                    <measurement group_id="O2" value="6.920" spread="3.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margin is the standard error of the estimated difference.</non_inferiority_desc>
            <p_value>0.025</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.634</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.816</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.927</ci_lower_limit>
            <ci_upper_limit>-0.341</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Post-procedure Provider Assessed Level of Difficulty Score</title>
        <description>Following the procedure, the obstetric provider performing the procedure will rate the ease of procedure on a 1-10 scale (1 being very easy and 10 being extremely difficult), ranging from 1 to 10. Higher scores indicate more difficulty, lower scores indicate less difficulty. A 10 point scale was used for this outcome, while an 11 point scale was used for the other 4 outcome measures (pain, anxiety, post-procedure pain and satisfaction).</description>
        <time_frame>Immediately Post-procedure, within approximately 15 minutes of final version attempt</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
            <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
          </group>
          <group group_id="O2">
            <title>Oxygen</title>
            <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Post-procedure Provider Assessed Level of Difficulty Score</title>
          <description>Following the procedure, the obstetric provider performing the procedure will rate the ease of procedure on a 1-10 scale (1 being very easy and 10 being extremely difficult), ranging from 1 to 10. Higher scores indicate more difficulty, lower scores indicate less difficulty. A 10 point scale was used for this outcome, while an 11 point scale was used for the other 4 outcome measures (pain, anxiety, post-procedure pain and satisfaction).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.136" spread="2.21"/>
                    <measurement group_id="O2" value="6.080" spread="3.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margin is the standard error of the estimated difference.</non_inferiority_desc>
            <p_value>0.944</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.742</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.543</ci_lower_limit>
            <ci_upper_limit>1.655</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During each version procedure (or attempt), a total average of up to approximately 30 minutes and through approximately 15 minutes post-procedure following the final version attempt.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nitrous Oxide</title>
          <description>Patients will receive nitrous oxide during the version procedure.
Nitrous Oxide: 50% nitrous oxide/50% oxygen via Nitronox delivery device</description>
        </group>
        <group group_id="E2">
          <title>Oxygen</title>
          <description>Patients will receive placebo (100% oxygen) during the version procedure.
Placebo: 100% oxygen via Nitronox delivery device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Transient headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen A. Smith, MD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>9199665136</phone>
      <email>ksmith@aims.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

